Shattuck Labs, Inc. Common Stock STTK

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

• The Motley Fool 24 ago

  What Shattuck Labs Stock Topped the Market on Monday

  Shattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.

  

• The Motley Fool 24 jul

  Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

  Shattuck Labs stock rose nearly 5% on Friday following JPMorgan Chase analyst Brian Cheng's initiation of coverage with an 'overweight' rating and $10 price target (35% upside). The bullish call was driven by positive clinical trial data for the company's lead drug candidate SL-325, a first-in-class antagonist antibody for inflammatory bowel disease, which showed a cleaner safety profile and stronger target engagement than competitors. The drug is scheduled to enter Phase 2 trials in Q3.

  

• Benzinga 10 jun

  Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

  Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced the pricing of a $75 million public offering consisting of 10.88 million shares at $4.00 per share and 7.87 million pre-funded warrants at $3.9999 per warrant. The offering is expected to close on June 11, 2026, with underwriters including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor.

  

• GlobeNewswire Inc. 10 jun

  Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

  Shattuck Labs, a clinical-stage biotechnology company developing DR3 blocking antibodies, announced the pricing of a public offering of 10.9 million shares at $4.00 per share and 7.9 million pre-funded warrants at $3.9999 per warrant, expected to raise approximately $75 million gross proceeds. The offering is expected to close on June 11, 2026, with Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor serving as joint bookrunning managers.